The present disclosure describes methods of determining the risk of developing breast cancer in a subject or determining whether a subject suffers from breast cancer. The methods can comprise detecting the expression level of microRNAs (miRNAs) hsa-miR-186-5p (SEQ ID NO: 77) and/or hsa-miR-409-3p (SEQ ID NO: 178) in a bodily fluid sample obtained from the subject and determining whether it is upregulated or downregulated as compared to a control, wherein the upregulation of hsa-miR-186-5p (SEQ ID NO: 77) and/or downregulation of hsa-miR-409-3p (SEQ ID NO: 178) indicates that the subject has breast cancer or is at risk of developing breast cancers. Also encompassed are methods of prognosis or diagnosis of breast cancer by detecting expression levels of combinations of miRNAs and using a score based on a panel of miRNA markers.